Deoxyspergualin: a new immunosuppressive drug for the treatment of auto-immune disease.
Deoxyspergualin: a new immunosuppressive drug for the treatment of auto-immune disease.
复制标题
脱氧精胍菌素：一种用于治疗自身免疫性疾病的新型免疫抑制药物。
作者：
D. Nikolic;Peter G. Kerr;H. Lan;G. Tesch;R. C. Atkins;R. C. Atkins
在过去的15年里，免疫抑制药物的发展是临床移植取得巨大成功的关键。虽然环孢素和FK506等药物可以预防同种异体移植排斥反应的发生，但它们表现出许多不良副作用，并且已被证明仅在抑制自身免疫性疾病方面部分有效。因此，人们一直在寻找具有更强抑制作用和更少副作用的新型免疫抑制剂。脱氧精瓜林（Deoxyspergualin）是一种细菌产物精瓜林的类似物，最初是从土壤共生的后孢子芽孢杆菌（Bacillus laterosporous）中纯化出来的[1,2]，是一种新的免疫抑制药物，已被证明在抑制移植排斥反应方面特别有效，在治疗自身免疫性疾病的实验模型中显示出很大的希望。近年来对脱氧桔皮灵在移植中的应用进行了综述[3,4]，本文将重点介绍脱氧桔皮灵在自身免疫性疾病中的作用及其作用机制。
The development of immunosuppressive drugs has been central to the dramatic success of clinical transplan tation achieved over the last 15 years. While drugs such as ciclosporin and FK506 can prevent the development of allograft rejection, they exhibit a number of adverse sideeffects and have proven only partially effective in sup pressing auto-immune diseases. Therefore, there is a con stant search to identify new immunosuppressive agents with more powerful inhibitory actions and fewer un wanted side-effects. Deoxyspergualin, an analogue of the bacterial product spergualin originally purified from the soil commensal Bacillus laterosporous [1, 2], is one new immunosuppressive drug which has proven particularly efficacious in suppressing transplant rejection and shows much promise in the treatment of experimental models of auto-immune disease. As the use of deoxyspergualin in transplantation has been recently reviewed [3, 4], this paper will focus upon the effects of the drug in auto immune disease and its mechanism of action.